CALLA trial: immunotherapy in locally advanced cervical cancer

We have read with deep interest the findings from the CALLA trial—a randomised, double blind, phase 3 study that enrolled 770 patients diagnosed with locally advanced cervical cancer. The participants received standard-of-care chemoradiotherapy along with either a fixed dose of 1500 mg durvalumab or a placebo administered every 4 weeks for 24 cycles, or until disease progression.1